alexa Ferric Pyrophosphate Citrate (Triferic), A Novel Therapy That Treats Anemia Of Inflammation And Overcomes Functional Iron Deficiency
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

12TH ANNUAL CONFERENCE ON Nephrology & Urology

Ajay Gupta and Raymond D Pratt
University of California, USA
Rockwell Medical, Inc., USA
ScientificTracks Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959-C1-042
Ferric Pyrophosphate Citrate (FPC) is a novel, highly soluble iron salt for parenteral delivery via hemodialysis solution. FPC donates iron directly and rapidly to transferrin, avoiding iron sequestration in the reticuloendothelial system. Randomized, placebo-controlled clinical trials in chronic hemodialysis (CKD 5HD) patients have demonstrated that FPC delivery by hemodialysis can maintain iron balance by replacing regular iron losses, while reducing ESA use and maintaining hemoglobin (Hgb). In the double-blind PRIME study, 104 iron replete (serum ferritin, 200 1000 μg/L) CKD 5HD patients received FPC or placebo for 36 weeks. The ESA dose was titrated to maintain Hgb in the target range; intravenous (IV) iron was administered for serum ferritin <200 μg/L. Prescribed ESA and IV iron doses were reduced by 35% (p=0.045) and 45% (p=0.028), respectively, in the FPC group, without increases in levels of serum ferritin, hepcidin or markers of oxidative stress/ inflammation. In two single blind phase 3 studies (CRUISE), iron replete CKD 5HD patients received FPC (N=299) or placebo (N=300) for 48 weeks; changes in ESA and IV/oral iron doses were prohibited. Hgb was maintained at baseline levels in FPC treated patients in both studies, whereas placebo treated patients developed iron restricted erythropoiesis. Mean change in Hgb from baseline to end of treatment was 3.6 g/L lower for placebo than for FPC (p=0.011). The safety profile of FPC was similar to placebo, with no anaphylaxis. No increases in incidence of intradialytic hypotension, cardiovascular events, or infections were observed with FPC compared with placebo. FPC is effective in treating functional iron deficiency in states of inflammation, including CKD 5HD.

Ajay Gupta received his MBBS degree and completed his residency in internal medicine at the All India Institute of Medical Sciences (New Delhi). He is currently an Adjunct Associate Professor of Medicine at the University of California at Irvine and Chief Scientific Officer at Rockwell Medical, Inc. He is the inventor of dialysate iron therapy using FPC, as well as the inventor of IV iron therapy using slow continuous infusion of FPC. He has published more than 40 papers in reputed journals.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version